title: Viewing the epigenetics of colorectal cancer through the window of folic acid effects.
abstract: In this issue of the journal (beginning on page 1552), Wallace and colleagues shed new light on the epigenetics of colorectal cancer by exploring the role of changes in DNA methylation in normal-appearing colon biopsies collected during a chemoprevention trial of folic acid. This study and the parent clinical trial will potentially further elucidate the long-studied role of folate in colon cancer development. In particular, the focus on the intermediate biomarker DNA methylation could provide a mechanistic link between folate exposure and colon cancer. Dietary or supplemental folate has complex interactions with important processes that may alter colon cancer development or progression, but this influence is likely altered by supplementation's timing and duration and whether in the setting of depleted or more typical, higher levels of folate. Despite decades of epidemiologic, molecular, and animal studies, answers to what effects these interactions have are complex, often contradictory. This perspective will place this study in context, looking at what it tells us and what it does not.
authors.affiliation: Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. manon.van.engeland@mumc.nl
authors.forename: Manon
authors.initials: M
authors.lastname: van Engeland
authors.forename: James G
authors.initials: JG
authors.lastname: Herman
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000235:genetics*; D019175:DNA Methylation / Q000187:drug effects*; D044127:Epigenesis, Genetic; D005492:Folic Acid / Q000627:therapeutic use*; D006801:Humans
chemical_list: D016588:Anticarcinogenic Agents; D005492:Folic Acid